Edition:
United Kingdom

Ignyta Inc (RXDX.OQ)

RXDX.OQ on NASDAQ Stock Exchange Capital Market

26.85USD
8:59pm GMT
Change (% chg)

$-0.08 (-0.28%)
Prev Close
$26.92
Open
$26.95
Day's High
$26.95
Day's Low
$26.83
Volume
680,259
Avg. Vol
374,045
52-wk High
$27.10
52-wk Low
$4.65

Select another date:

Fri, Dec 29 2017

BRIEF-Ignyta To Commence Phase 1 Study For RXDX-106 In Early 2018

* IGNYTA REPORTS FDA CLEARANCE OF IND FOR RXDX-106, A NOVEL IMMUNOMODULATORY AGENT AND TYRO3, AXL, MER (TAM) INHIBITOR

BRIEF-Ignyta To Pay Roche Termination Fee Of About $58 Mln If Merger Is Terminated

* IGNYTA SAYS MERGER DEAL WITH ROCHE CONTAINS, UNDER CERTAIN CIRCUMSTANCES, REQUIREMENT FOR CO TO PAY ROCHE TERMINATION FEE OF ABOUT $58 MILLION - SEC FILING Source text: (http://bit.ly/2CUTeTW) Further company coverage:

Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion

Swiss drugmaker Roche will buy U.S. cancer drug specialist Ignyta Inc for $1.7 billion in an agreed deal to broaden its oncology portfolio, the firms said on Friday.

Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion

Swiss drugmaker Roche will buy U.S. cancer drug specialist Ignyta Inc for $1.7 billion (£1.43 billion) in an agreed deal to broaden its oncology portfolio, the firms said on Friday.

UPDATE 2-Roche to buy U.S. cancer drugmaker Ignyta for $1.7 bln

Dec 22 Swiss drugmaker Roche will buy U.S. cancer drug specialist Ignyta Inc for $1.7 billion in an agreed deal to broaden its oncology portfolio, the firms said on Friday.

Roche to buy US cancer drugmaker Ignyta for $1.7 bln

Dec 22 Swiss drugmaker Roche said on Friday it would buy U.S. cancer drugmaker Ignyta Inc for $1.7 billion.

BRIEF-Roche To Acquire Ignyta For $1.7 Bln

* IGNYTA INC SAYS ROCHE TO ACQUIRE IGNYTA FOR US$ 27.00 PER SHARE

Exclusive: U.S. cancer drugmaker Ignyta in advanced sale talks - sources

Ignyta Inc is in advanced talks to sell itself, people familiar with the matter said on Thursday, just three years after the U.S. cancer drugmaker became a public company focused on precision drugs and diagnostics.

BRIEF-Ignyta announces new data highlighting immune modulation of RXDX-106 at the society for immunotherapy of cancer meeting

* Ignyta announces new data highlighting immune modulation of RXDX-106 at the society for immunotherapy of cancer (sitc) meeting Source text for Eikon: Further company coverage:

BRIEF-Ignyta Inc files for potential mixed shelf offering; size not disclosed

* Ignyta Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​ Source text: (http://bit.ly/2gt6zxh) Further company coverage:

Select another date: